arrow
C

C. Buddy Creech

Vanderbilt University Medical Center
H指数:45
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination

评估两种分数剂量皮内接种MVA-BN方案与标准剂量疫苗接种的安全性和免疫原性比较

Vaccine
IF3.5
2025-11-290
PRE
Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews

临床免疫接种安全性评估(CISA)项目:COVID-19疫苗咨询和病例审查

Vaccine
IF3.5
2025-09-270
OAAI
Immunologic profiling of the infant immune response to whole-cell and acellular pertussis vaccines

婴儿对全细胞和无细胞百日咳疫苗的免疫应答免疫学分析

2025-08-110
OA
Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers

纵向Meta-cohort研究方案:采用系统生物学方法识别疫苗安全性生物标志物

Vaccine
IF3.5
2025-07-260
OA
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age

一项关于两种四价季节性流感疫苗(Fluzone®或Flublok®)在18-45岁健康成年人中,单独使用或与两种佐剂(AF03或Advax-CpG55.2)联合使用时的安全性、反应原性和免疫原性的I期研究

VACCINE
IF3.5
2025-04-010
PRE
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens

抗神经氨酸酶和抗血凝素stalk对不同流感A(H7N9)疫苗方案的反应

VACCINE
IF3.5
2025-02-010
PRE
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis

囊性纤维化患者中头孢吡肟,美罗培南和哌拉西林-他唑巴坦的群体药代动力学模型

2024-09-300
PRE
Safety and Immunogenicity of an mRNA-1273 Booster in Children

mRNA-1273助推器在儿童中的安全性和免疫原性

2024-08-190
OAAI
Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface
IMMUNITY
IF26.3
2024-06-010
PRE
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
2023-10-162
PRE
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial

不同启动方案后延迟异源禽流感a (H7N9) 疫苗加强的安全性和免疫原性: 一项随机临床试验

2023-07-193
OA
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients

群体药代动力学和目标达成分析,以确定重症患者头孢吡肟的合理经验给药策略

2023-04-183
OA
Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022

2021年11月至2022年3月对接受辉瑞-BioNTech新型冠状病毒肺炎疫苗的5-11岁美国儿童进行多系统炎症综合征监测

2023-02-233
OA